Ongoing trials involving CD19 CAR-T-cell therapies in SLE are of particular interest, as they offer a broader depletion of autoreactive B cells, including those residing in inflamed tissues (5, 19). This evidence concerns the gene CD19 and systemic lupus erythematosus.